MTEK
QXL
NXTS

Weiss Amitay

Known title: DirectorCIK: 0001826620

Weiss Amitay's purchase track record

Weiss Amitay has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.

PurchaseStockAmount3 months6 months
6/18/2024QXL$3Kpendingpending

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 2, 2026

MTEK Completes Diamond Ultra V2 Platform, Wins $10M Airborne Order. Maris‑Tech announced the completion of its Diamond Ultra V2 platform, a next‑generation video and AI solution. The company also disclosed a record US$10 million contract for advanced video systems on next‑generation airborne defense platforms, its largest order to date. In the past week the shares were listed among multiple information‑technology stocks moving in after‑hours and pre‑market sessions, showing heightened market activity.

this person other insiders at MTEK

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 29, 2026

Quantum X Labs Names Yakov Baranes Sole CEO; Files New Patents. Quantum X Labs announced that Co-CEO Amihay Hadad has stepped down, with Yakov Baranes appointed as the sole CEO effective immediately. The company also filed new U.S. patent applications for quantum authentication and circuit watermarking technologies. These developments highlight a shift in leadership and continued focus on expanding its quantum security and defense platform capabilities.

this person other insiders at QXL

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 7, 2026

NXTS Unit MitoCareX Bio Launches Cloud‑Based Drug Discovery Platform. MitoCareX Bio, a unit of Nexentis Technologies, has deployed its computational drug discovery infrastructure on the Google Cloud Platform. The deployment is intended to improve the speed and scalability of its biotech research services. This development comes as the stock is trading near its recent support level after a period of low momentum.

this person other insiders at NXTS

Transaction History

MTEK▲ Buy$0
QXL▼ Sell$61K
NXTS▲ Buy$0
NXTS▲ Buy$0
QXL▲ Buy$3K
NXTS▲ Buy$0
QXL▲ Buy$0

We use analytics to understand how market-wall is used. No personal data is sold.